BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Week in Review: Sinopharm Group Pays $252 Million for Majority Stake in Winteam Pharma


3/5/2013 12:45:43 PM

by Richard Daverman, PhD

March 2, 2013 -- Sinopharm paid $252 million to purchase a 57% stake in China’s Winteam Pharma, a TCM maker; OrbiMed Advisors will close its second Asia healthcare private equity fund later this year, a fund that will invest mainly in China and India; China Grand Pharma announced a $20 million oncology drug JV with HuangShi Feiyun Pharma; Fosun Pharma formed a China distribution JV with Atrium Innovations, a Canadian dietary supplement company; Crystal Pharmatech of Suzhou and US-based Particle Sciences set up a CRO partnership; the SFDA proposed new drug review guidelines that will prioritize innovation and shorten review timelines; Polaris Group of San Diego will build a $50 million drug biotech manufacturing facility in Chengdu; Mindray Medical’s 2012 revenues topped $1 billion for the first time; and Pfizer received China approval for Xalkori, a treatment for NSCLC that has the ALK mutation. More details….

Stock Symbol: (HK: 0570) (HK: 00512) (SHA: 600196; HK: 2196) (TSX: ATB) (NYSE: MR) (NYSE: PFE)



Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES